Courses

Title

Category

Credits

Event date

Cost

2022 EGFR+ Lung Cancer Rapid Recap: The Evolving State of the Science in EGFR+ NSCLC—A Closer Look at the Paradigm-Shifting Synergy of Safety, Efficacy, and Equitable Access

Oncology

ACPE Pharmacy
AMA PRA Category 1 Credit™
ANCC
ICPE
Participation

$0.00

This Rapid Recap will provide a responsive, timely, and incisive overview of data presented at the 2022 Clinical Oncology Annual Meeting, and offer expert insights into the shifting management landscape for metastatic EGFR+ NSCLC. These data will be placed in context of the established paradigm, with key scientific messages and pivotal points highlighted for audience takeaway. The session will conclude with a patient-led roundtable evaluating the multifarious burden of financial toxicity on optimal and equitable outcomes in NSCLC.

New Horizons in Unresectable Stage III NSCLC: A Case-based Exploration of Evolving Data and the Emergence of Immunotherapy

Oncology

ACPE Pharmacy
AMA PRA Category 1 Credit™
ANCC
Participation

$0.00

Join our Expert Faculty, Drs. Joel W. Neal, MD, PhD and Victoria Sherry, DNP, CRNP, AOCNP as they discuss treatment principles across the continuum of care in unresectable, stage III NSCLC.

New Horizons in Unresectable Stage III NSCLC: A Case-based Exploration of Evolving Data and the Emergence of Immunotherapy

Oncology

ACPE Pharmacy
AMA PRA Category 1 Credit™
ANCC
Participation

$0.00

Join our Expert Faculty, Drs. Joel W. Neal, MD, PhD and Victoria Sherry, DNP, CRNP, AOCNP as they discuss treatment principles across the continuum of care in unresectable, stage III NSCLC.

Navigating Novel Terrain in Anemia of Chronic Kidney Disease: A Patient-centric Review of Disease State, Current Chasms in Care, and the Future Promise of HIF-PH Inhibition

Nephrology

ACPE Pharmacy
AMA PRA Category 1 Credit™
ANCC
Participation

$0.00

To facilitate timely diagnosis and rapid treatment initiation for anemia in CKD, the multidisciplinary and interprofessional CKD-anemia treatment team should be aware of the significant impact of anemia on patient quality of life, progression of CKD, and cardiovascular events. Erythropoietin-stimulating agents (ESAs) are associated with significant cardiovascular safety-related concerns, but the emergence of the oral hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) may improve erythropoiesis without the undesirable downstream effects of ESAs.

IV Iron Expert Exchange: Data-driven Debates on the Revolutionary Role of IV Iron in Heart Failure